UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000041108 |
|---|---|
| Receipt number | R000046947 |
| Scientific Title | Validation study on the effects on liver function and skin barrier function by intake of adlay |
| Date of disclosure of the study information | 2020/07/15 |
| Last modified on | 2021/01/13 09:33:55 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Validation study on the effects on liver function and skin barrier function by intake of adlay
Acronym
Validation study on the effects on liver function and skin barrier function by intake of adlay
Scientific Title
Validation study on the effects on liver function and skin barrier function by intake of adlay
Scientific Title:Acronym
Validation study on the effects on liver function and skin barrier function by intake of adlay
Region
| Japan |
Condition
Condition
Healthy Adults
Classification by specialty
| Not applicable |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
Evaluate the effects of liver function and skin barrier function by adlay tea intake for 8 weeks.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
-liver function (AST, ALT, gamma-GTP )
-skin hydration (Transepidermal water loss, Moisture)
At the beginning of the test or after the intake for 8 weeks.
Key secondary outcomes
-Blood test (total protein, albumin, ,blood neutral fat (TG), total cholesterol, HDL-cholesterol, LDL-cholesterol, urea nitrogen , ALP, CPK, total bilirubin, uric acid, urea nitrogen, creatinine, sodium, potassium, chlorine, calcium, phosphorus, magnesium, LDH, white blood cell count, red blood cell count, hemoglobin, hematocrit, platelet count, MCV, MCH, MCHC)
-Physical examination (body height, weight, BMI, blood pressure, pulse)
-Food questionnaire
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Intake 500mL of adlay tea daily for 8 weeks.
Interventions/Control_2
Intake 500ml of barley tea daily for 8 weeks.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 65 | years-old | > |
Gender
Female
Key inclusion criteria
1.Persons who received a sufficient explanation of the purpose and contents of the exam, have the capacity to consent, applied with free will with sufficient understanding, and agreed to participate with a written document
2.Japanese women who are 20 years old or more and under 65 years old
3.Persons who are the bottom 70 of the value of skin hydration at screening
Key exclusion criteria
1.Persons who have chronic illness, receiving medication, have a serious disease history
2.Persons who are allergic to the test food
3.Persons who usually take a large amount of test food
4.Persons whose ALT or AST is over 51 U/L at screening
5.Persons whose gamma-GTP is over 101 U/L at screening
6.Persons whose habitually consume higher amount of alcohol (>60g alcohol/day)
7.Persons who have skin disease such as atopic dermatitis, urticaria, eczema and dermatitis.
8.Persons who regularly use medicines, specified insurance foods, health foods, etc. that may affect liver function and skin function
9.Persons who have participated in other tests within the first month before the start of the test, or those who intend to participate in another exam after consenting to this exam
10.Persons who are pregnant, planning or hoping to be pregnant during the study period, breastfeeding
11.Persons who were judged as inappropriate for subjects by the principal investigator
Target sample size
70
Research contact person
Name of lead principal investigator
| 1st name | Hirohito |
| Middle name | |
| Last name | Ishikawa |
Organization
Healthcare Systems Co., Ltd.
Division name
Research and Development Department
Zip code
105-0004
Address
Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN
TEL
03-6809-2722
ishikawa@hc-sys.jp
Public contact
Name of contact person
| 1st name | Hitomi |
| Middle name | |
| Last name | Izumi |
Organization
Healthcare Systems Co., Ltd.
Division name
Research and Development Department
Zip code
105-0004
Address
Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN
TEL
03-6809-2722
Homepage URL
izumi@hc-sys.jp
Sponsor or person
Institute
Healthcare Systems Co., Ltd.
Institute
Department
Personal name
Funding Source
Organization
Cabinet Office
Organization
Division
Category of Funding Organization
Government offices of other countries
Nationality of Funding Organization
Other related organizations
Co-sponsor
Oyama city
Name of secondary funder(s)
IRB Contact (For public release)
Organization
The Ethics Committee of Healthcare Systems Co., Ltd.
Address
Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN
Tel
03-6809-2722
soumu@hc-sys.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2020 | Year | 07 | Month | 15 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
70
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2020 | Year | 06 | Month | 18 | Day |
Date of IRB
| 2020 | Year | 06 | Month | 18 | Day |
Anticipated trial start date
| 2020 | Year | 08 | Month | 08 | Day |
Last follow-up date
| 2020 | Year | 12 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2020 | Year | 07 | Month | 15 | Day |
Last modified on
| 2021 | Year | 01 | Month | 13 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046947
